Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBT Margin (2020 - 2025)

Historic EBT Margin for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 29.5%.

  • Tango Therapeutics' EBT Margin rose 2803200.0% to 29.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 150.99%, marking a year-over-year increase of 1329600.0%. This contributed to the annual value of 309.24% for FY2024, which is 310600.0% down from last year.
  • Tango Therapeutics' EBT Margin amounted to 29.5% in Q3 2025, which was up 2803200.0% from 1220.31% recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' EBT Margin registered a high of 29.5% during Q3 2025, and its lowest value of 1220.31% during Q2 2025.
  • Moreover, its 5-year median value for EBT Margin was 419.8% (2022), whereas its average is 412.22%.
  • As far as peak fluctuations go, Tango Therapeutics' EBT Margin surged by 2892600bps in 2023, and later crashed by -10920800bps in 2025.
  • Over the past 5 years, Tango Therapeutics' EBT Margin (Quarter) stood at 382.59% in 2021, then dropped by -18bps to 452.49% in 2022, then dropped by -25bps to 565.57% in 2023, then crashed by -62bps to 913.8% in 2024, then surged by 103bps to 29.5% in 2025.
  • Its EBT Margin was 29.5% in Q3 2025, compared to 1220.31% in Q2 2025 and 738.91% in Q1 2025.